H.C. Wainwright raised the firm’s price target on Adma Biologics to $18 from $10 and keeps a Buy rating on the shares. the company reported substantial top- and bottom-line outperformance and its guidance was increased yet again, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADMA:
- Adma Biologics price target raised to $20 from $15 at Cantor Fitzgerald
- ADMA Upcoming Earnings Report: What to Expect?
- ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024
- ADMA Biologics Appoints Brad Tade as New CFO and Treasurer
- Adma Biologics price target raised to $15 from $10 at Cantor Fitzgerald